Business Context and Reporting Period
This Form 8-K, dated September 24, 2011, reports a strategic restructuring by RXi Pharmaceuticals Corporation, which changed its name to Galena Biopharma, Inc. ("Galena") on September 26, 2011. The filing details the planned separation of the company into two entities: Galena, focusing on late-stage oncology drug development, and a newly formed subsidiary, RXi Pharmaceuticals Corporation ("RXi"), which will develop RNAi-based therapies. The transaction involves the contribution of substantially all RNAi-related assets to RXi and a proposed partial spin-off of RXi to Galena stockholders.
Key Financial Metrics and Agreements
- Asset Contribution: Galena contributed approximately $1.5 million in cash and substantially all RNAi-related technologies, licenses, and the Worcester, Massachusetts laboratory facility to RXi.
- RXi Financing: Institutional investors agreed to purchase $9.5 million of RXi Series A Preferred Stock at the closing of the spin-off.
- Bridge Loan: Investors agreed to lend up to $1.5 million to RXi via secured convertible promissory notes to fund operations prior to closing. The initial tranche of $500,000 was issued on September 24, 2011.
- Galena Investment: Investors agreed to purchase $2.5 million of Galena common stock, with closing expected on September 30, 2011.
- Milestone Payments: RXi agreed to make future milestone payments to Galena of up to $45 million ($15 million and $30 million) if RXi achieves annual net sales of $500 million and $1 billion, respectively.
- Transaction Costs: RXi agreed to reimburse Galena and investors up to $350,000 for transaction costs.
Material Changes Versus Prior Period
The filing represents a material change in corporate structure and operations rather than a standard financial reporting period. Key changes include:
- Corporate Name and Symbol: The company name changed from RXi Pharmaceuticals Corporation to Galena Biopharma, Inc., with a new NASDAQ trading symbol "GALE" (RXi expected to trade as "RXII").
- Asset Transfer: Substantial RNAi assets, including the lead product candidate RXI-109, were transferred to the new RXi subsidiary.
- Executive Changes: Robert E. Kennedy resigned as Chief Financial Officer; Mark J. Ahn assumed the CFO duties. Key scientific officers (Dr. Anastasia Khvorova and Dr. Pamela Pavco) transferred employment to RXi.
- Office Relocation: Galena relocated its executive offices from Worcester, Massachusetts, to Lake Oswego, Oregon.
Guidance, Outlook, Risks, and Contingencies
Outlook and Conditions: The partial spin-off and RXi financing are subject to customary closing conditions, including the registration of the distribution of spin-off shares under the Securities Act of 1933. There is no assurance that the transactions will be completed.
Risks and Contingencies:
- Termination Date: The securities purchase agreement may be terminated if the partial spin-off has not occurred by February 22, 2012.
- Default Scenario: If the closing does not occur by the maturity date of the Bridge Loan notes, 50% of the outstanding loan balance will convert into 51% of RXi's post-conversion common stock. RXi would remain a private company, and Galena would be obligated to guarantee the repayment of the remaining loan balance.
- Capitalization Uncertainty: The actual number of spin-off shares and the final capitalization of RXi are not yet established and will be determined closer to the completion of the spin-off.
- Guarantees: Galena has guaranteed the repayment of the RXi convertible notes and pledged all shares of RXi common stock it holds as security.
Important Facts for Investor Verification
- Verify the status of the registration statement required for the distribution of RXi spin-off shares to Galena stockholders.
- Confirm the final capitalization of RXi and the exact number of shares to be distributed in the spin-off.
- Monitor the February 22, 2012 deadline for the completion of the spin-off to avoid the default conversion scenario of the Bridge Loan.
- Review the terms of the $9.5 million Series A Preferred Stock, including the 7% dividend rate and full-ratchet anti-dilution protection.
- Assess the impact of the $45 million potential milestone payments on Galena's future revenue recognition.